KLIFO is a leading North European drug development consultancy. We offer consulting and operational services across all areas of drug development. We have significant experience in partnering with international companies across pharmaceutical and biotech industries.

We offer end to end solutions across all drug development areas, including strategic project management, regulatory affairs, clinical development, clinical trial supply, quality assurance (QA), Chemistry Manufacturing and Controls (CMC) development, non-clinical development and pharmacovigilance concerning the development of pharmaceutical products. We provide strategic advice as well as operational support in all these areas, and we partner with clients on portfolio strategies, project development strategies and project execution.

With offices in Denmark, Germany, Sweden and the Netherlands, and more than 150 highly qualified staff, all with solid industry experience, we can assemble a team of experts to support the efficient advancement of your project. Our project teams represent the full breadth of expertise, competences and experience for successfully taking our clients’ drug development projects from discovery to market.

No matter the phase, scale or therapy area, our experts can help plan, manage and execute your drug development project. Whether your organisation is challenged with time, resources or expertise, we can assemble a team of relevant expert consultants to assist you.

You can insource our consultants to your organisation or outsource your project to us. Our solutions are based on close collaboration with you and your colleagues. We strive to build flexible and trust-based partnerships in which we work as an integrated part of your team.

Through collaboration, we can harness our combined expertise and ensure proper project implementation to ensure that your organisation benefits in both the short and long term.

At KLIFO we believe in collaboration, both internally among our staff and together with the companies we partner with. Only through collaboration is it possible to foresee and mitigate the many complexities associated with developing a new medical drug or bringing products to market.
Each and every drug development process is unique – acknowledging and embracing this is key to successfully bringing a new product to market. At KLIFO our starting point is to always listen to our clients’ needs and aspirations and based on this we can develop customised and efficient solutions.
The drug development process can take many years and the path can be costly and complex. Yet, at KLIFO we always have confidence in each other’s capacity, and this helps us to stay positive and develop novel solutions, also when faced with a difficult challenge. We have the same approach to working with our clients; building trust-based relationships plays a pivotal role in how we work.
Each milestone along the drug development journey requires unique skills and special expertise. KLIFO always strives to attract and retain the leading experts from all fields of drug development. We invest in our people and encourage their growth and development, so they can continue to offer the best possible solutions for our clients.

Key events at KLIFO


Rasmus Nelund appointed CEO of KLIFO


Gilde Healthcare acquires majority stake in KLIFO to support international growth ambitions


KLIFO acquires MediServ and establishes an office in Eindhoven

For the 6th year in a row, KLIFO receives the prestigious Gazelle prize


KLIFO office established in Sweden

KLIFO acquires Munich-based medicomp GmbH

Quality Assurance Solutions


KLIFO becomes a member of Trial Nation


CMC Development Solutions established

KLIFO joins the Danish public-private NEXT partnership


Regulatory Affairs Solutions established


Pharmacovigilance Solutions established


Alejandra Mørk acquires KLIFO and joins as CEO

Drug Development Counselling Solutions established


Clinic Trial Supply Solutions established 


KLIFO joins PSNResearch


KLIFO is founded in Denmark as a Clinical Research Organisation (CRO)

Management team 

Rasmus Nelund


Rasmus Nelund joined KLIFO on 1 May 2023 and brings more than 20 years of experience as a leader in the international life science industry. Prior to joining KLIFO, Rasmus worked 10 years as Corporate Vice President at NNIT A/S, where he led the company’s strong international growth by supporting life sciences companies in their business transformation fuelled by technological change. He did this in senior leadership positions focusing on customer success, strategic execution, M&A and organisational development. Before joining NNIT, he co-founded the Clinical IT consulting company Herax A/S and served as CEO at Pipeline Biotech A/S, a CRO, specialised in preclinical research services.

Direct/mobile: + 45 44 778 793
Email: moc.ofilk@dnuleN.sumsaR

Hanne Wulff Nielsen


Hanne holds a Ph.D. in biopharmaceutics and has more than 25 years of pharma industry experience within pharmaceutical product development, business development, project and vendor management, marketing and medical affairs. She joined KLIFO in January 2019 and prior to this she has held specialist and leadership positions in large pharmaceutical companies and in biotech.

Direct/mobile: + 45 44 222 903
Email: moc.ofilk@neslein.ennah

Christina Vinum


Christina Vinum joined KLIFO in February 2011 as Senior Clinical Trial Supply Coordinator and became Director of Clinical Trial Supply in January 2012 and VP: Clinical Trial Supply in 2014. Christina has more than 15 years experience with clinical trial supplies, first at Nycomed from 2001 as Clinical Trial Supply Coordinator and, from January 2009, as Head of Clinical Supply for Nycomed CTS departments in Denmark and Germany.

Direct/mobile: +45 44 222 960
Email: moc.ofilk@muniv.anitsirhc

Anne Tingsgård


Anne Tingsgård holds a Master of Pharmacy degree and joined KLIFO in September 2014. She has more than 30 years’ regulatory affairs experience from both big pharma and private consulting, including two years as CEO and COO in A-consult.

Direct/mobile: +45 44 222 940
Email: moc.ofilk@draagsgnit.enna

Rikke Dencker

Senior Director HR and Lawyer

Rikke holds an MSc of Law and has more than 10 years of experience working as a lawyer at the Danish Chamber of Commerce advising companies within all aspects of employment law. She joined KLIFO in March 2021. Before that Rikke held a position as Nordic Head of HR at SOS international.

Direct/mobile: +45 44 778 715

Christoph Kapitza

Managing Director, KLIFO GmbH

Dr. Christoph Kapitza joined KLIFO on 1 August 2022 and brings more than 25 years of research experience in the development of drugs, devices and drug-device combination products. He has a proven track record of successfully executing drug development strategies and has held several leadership positions in the pharma industry. Dr. Kapitza has been Principle Investigator in approx. 90 early and later phase studies, and he has been a consultant in relation to clinical development plans (phase I through to post-marketing studies) for several top global pharma companies.

Direct/mobile: +49 160 765 1092
Email: moc.ofilk@aztipaK.hpotsirhC

René Pedersen


René Pedersen holds a Graduate Diploma degree and an MBA from Copenhagen Business School and joined KLIFO on 1 April 2023 as Chief Financial Officer.

René brings more than 25 years of international experience from leadership positions in life science and pharma consulting. Previously, René has worked as CFO at DanBred and as CFO and CVP at NNE. Between 1998 and 2016, René worked for Novo Nordisk in various leadership positions being responsible for finance and corporate strategies.

Direct/mobile: + 45 44 778 792
Email: moc.ofilk@nesredeP.eneR

Randi Rahbæk

Senior Director

Randi holds a MSc in Pharmacy and joined KLIFO in January 2021. She has more than 20 years of experience within people leadership, drug development and clinical operations excellence and has been with large, mid-sized and small pharma companies as Director for Trial Operations and Business Support.

During her career, Randi has been operational responsible for planning and execution of global clinical development programs from early stage to the post-approval phase.

Direct/mobile: + 45 44 778 704
Email: moc.ofilk@keabhar.idnar

Erik Zobel

Senior Director, QP & RP

Erik has 20+ years of solid experience with all quality aspects of the pharmaceutical industry, including experience as Qualified Person and lead auditor. He joined KLIFO in April 2022 and prior to this, he was head of QA for a Danish pharmaceutical company. Erik has worked in various leadership positions in a number of biotech and pharmaceutical companies. He holds a Master in Pharmacy from University of Copenhagen and a Graduate Diploma in Business Administration from Copenhagen Business School.

Direct/mobile: +45 44 778 759

Board of Directors

Niels Peder Nielsen

Chairman of the Board

Niels Peder Nielsen is chairman, board member and investor in various technology companies. He also serves as senior advisor to Bain & Company. Niels Peder was deputy-CEO of the Novo Nordisk Foundation and before that a senior partner with Bain & Company.

Niels Peder has 25+ years of experience from professional services, and has worked extensively with clients in biotech and pharma, as well as with companies owned by private equity funds. Niels Peder holds an M.Sc from Massachusetts Institute of Technology, and a B.Sc from Copenhagen Business School.

Alejandra Mørk

Strategic Development Advisor

Alejandra Mørk, PhD and MSc Pharm, has more than 30 years of experience in drug development and life cycle management. In 2008, Alejandra acquired KLIFO to build an international end to end drug development consultancy. From 2008 to 2023 she was CEO of the company. Prior to acquiring KLIFO, Alejandra spent 18 years at Nycomed Pharma in various leadership positions in Project Management, Clinical Development and Regulatory Affairs and was overall responsible for Drug Development.

Member of the Board of Directors at the Danish industry association Danish Bio and at Scandion Oncology.

Rafael Natanek

Board Member

Rafael Natanek is partner in the private equity team of Gilde Healthcare.  He is involved with deal origination, deal execution and serves on the supervisory boards of investee companies. Rafael is co-responsible for portfolio management activities. Prior to joining Gilde Healthcare, Rafael was partner at Bain & Company in London, where he advised private equity funds on healthcare transactions, and pharmaceutical and medtech companies on strategy, organization and commercial issues. Prior to Bain, he was with McKinsey & Company. Rafael holds a MSc in Chemical Engineering from Lund Institute of Technology, and a MSc in Biomedicine from Lund University, Sweden. He did his thesis at UC Berkeley, California.

Redmar Koene

Board Member

Redmar Koene is an investment professional at Gilde Healthcare. He is involved with deal origination and deal execution and serves on the supervisory boards or equivalent of investee companies like KLIFO and Synexa (bioanalytical CRO). In addition, he worked with Symeres (drug discovery CRO) on strategy and M&A, as well as with several other companies on executing successful buy-and-build agenda’s. Prior to joining Gilde Healthcare, he worked as investment professional at a Swiss-based investment company, investing in both listed as non-listed companies. Redmar has a MSc Finance and a MSc Accounting.

Mette Kirstine Agger

Board Member

Mette Kirstine was previously co-founder and CEO of 7TM Pharma A/S and has a broad international experience within biotech/life science covering business development and licensing, management and financing.

Mette has been appointed to numerous board positions both in private and public companies. Mette Kirstine Agger graduated as Biologist from the University of Copenhagen and has an MBA.